Biolog-id announces the opening of its first two subsidiaries in Spain and Italy12/11/2017 - Biolog-id, a developer of global solutions for the management of sensitive health products (red blood cells, plasma, platelets, chemotherapy preparations) based on RFID (Radio Frequency Identification) technology, has just opened its first two commercial subsidiaries in Spain and in Italy.
This first phase is part of Biolog-id's strategy of international expansion, as these two countries are a significant growth driver for RFID traceability of health products.
Biolog Iberica was created in Barcelona and covers the Spanish and Portuguese markets.
The Italian subsidiary, Biolog Italia, is based in Milan. These two entities, which have been operational since September 2017, are headed by Biolog-id President Pierre Parent and report to a regional sales manager.
The objectives of these subsidiaries are to develop close relationships with hospitals and blood centres, to answer invitations to tender and to propose solutions in line with their needs.
"The relevance of our solutions is driving global demand and we are receiving a growing number of requests from our clients. These new establishments allow Biolog-id to increase the number of users of its healthcare solutions and accelerate its growth internationally, while providing direct local support to customers," says Pierre Parent.
Biolog-id was founded in 2005 and develops solutions for managing sensitive health products based on an innovative concept that combines: a health product, an electronic chip, a range of encoding and reading equipment and software that provides real-time data processing. All of this allows healthcare facilities to effectively monitor and manage products, from their preparation to the patient’s bed.
After many years of perseverance from R&D, followed by a long process of validation of its solutions by Health Authorities, Biolog-id is now in its growth phase. In 2016, the company achieved a turnover of €7m, marking the beginning of its commercial development. The 5-year development plan forecasts an annual increase in turnover of 30 to 50% on average per year.
The reliability of its solutions and a portfolio of more than 100 patents filed in France and worldwide make Biolog-id the number one leader in the monitoring and management of sensitive health products by RFID. The company's headquarters are located in Paris, and it has a manufacturing facility in Bernay (Eure). It has 46 employees and plans to recruit new staff members in France and abroad to support its growth. www.biolog-id.fr
Biolog-id receives financial support from Xerys. www.xerys.com